Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

660
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

862
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
862
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

422
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
422

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The OMERACT core domain sets for calcium pyrophosphate deposition disease.

Seminars in arthritis and rheumatism·2026
Same author

Identifying candidate core domains for clinical trials in systemic sclerosis-associated Raynaud's phenomenon and digital ulcers.

Seminars in arthritis and rheumatism·2026
Same author

Suitability of the Oxford Shoulder Score for measuring pain in clinical trials evaluating interventions for people with shoulder disorders according to the OMERACT filter 2.2.

Seminars in arthritis and rheumatism·2026
Same author

Revista panamericana de salud publica = Pan American journal of public health·2026
Same author

Revista panamericana de salud publica = Pan American journal of public health·2026
Same author

Suitability of the Numerical Pain Rating Scale for measuring pain in clinical trials evaluating interventions for people with shoulder disorders according to the OMERACT filter 2.2.

Seminars in arthritis and rheumatism·2026

Related Experiment Video

Updated: Feb 28, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.2K

WITHDRAWN: Celecoxib for rheumatoid arthritis.

Sarah E Garner1, Dogan Fidan, Ruth R Frankish

  • 1Science Policy and Research, National Institute for Health and Care Excellence (NICE), MidCity Place, 71 High Holborn, London, UK, WC1V 6NA.

The Cochrane Database of Systematic Reviews
|June 10, 2017
PubMed
Summary
This summary is machine-generated.

Celecoxib effectively manages rheumatoid arthritis (RA) symptoms, similar to traditional NSAIDs, with fewer gastrointestinal issues in the short term. However, long-term benefits and cost-effectiveness require further consideration for RA patients.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice
06:54

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice

Published on: November 15, 2024

2.8K

Related Experiment Videos

Last Updated: Feb 28, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.2K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice
06:54

Author Spotlight: Enhanced Method for Evaluating Analgesic Effects — Dual Hind Paw Carrageenan Injection in Mice

Published on: November 15, 2024

2.8K

Area of Science:

  • Rheumatology
  • Pharmacology
  • Gastroenterology

Background:

  • Rheumatoid arthritis (RA) is a systemic autoimmune disease causing joint inflammation.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) manage RA symptoms but pose risks of gastrointestinal (GI) toxicity.
  • Selective COX-II inhibitors, like celecoxib, were developed to mitigate GI toxicity associated with traditional NSAIDs, though at a higher cost.

Purpose of the Study:

  • To systematically review the efficacy and safety of celecoxib for managing rheumatoid arthritis (RA).
  • To evaluate celecoxib's effectiveness compared to placebo and other NSAIDs in RA patients.
  • To assess the gastrointestinal safety profile of celecoxib in the context of RA treatment.

Main Methods:

  • Systematic review of eligible randomized controlled trials (RCTs) up to August 2002.
  • Inclusion of five RCTs involving 4465 participants, some also with osteoarthritis (OA).
  • Comparison of celecoxib against placebo, naproxen, diclofenac, and ibuprofen.

Main Results:

  • Celecoxib demonstrated comparable symptom control to active NSAID comparators (naproxen, diclofenac, ibuprofen).
  • Significantly higher ACR 20 improvement rates were observed with celecoxib (51-52%) versus placebo (29%) at week 4.
  • Short-term data indicated reduced upper GI complications with celecoxib, but long-term maintenance of this benefit and efficacy in patients on low-dose aspirin remain uncertain.

Conclusions:

  • Celecoxib offers comparable efficacy to traditional NSAIDs for RA symptom management.
  • Short-term reduction in GI complications with celecoxib is supported, but long-term data are inconclusive.
  • The increased cost of celecoxib must be weighed against uncertain long-term GI benefits and potential lack of added advantage in patients on aspirin.